WaveMan
WaveMan · Company
PTIX · Protagenic Therapeutics, Inc.\New
> Search tickers & screens ⌘K
LIVE
← All companies

PTIX Protagenic Therapeutics, Inc.\new (PTIX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001022899
Quote by TradingView
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

What the filings say about PTIX

Insiders, 180 days
+$30.7K net bought
1 buyer

Protagenic Therapeutics, Inc.\new insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Protagenic Therapeutics, Inc.\new insiders bought a net $30.7K of stock across 10 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
ARMEN GARO H
EXEC. CHAIR & PRINCIPAL OFF
BUY
2026-08-24 SECtraded 2026-08-21
20,000
$13.0K
-31.8%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Aug 20, 2026.
  • The trade is 27.2% of the 73,533 shares held after it.
  • No other insider bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: EXEC. CHAIR & PRINCIPAL OFF ARMEN GARO H bought about $13.0K of PTIX on Aug 21, 2026, the largest insider purchase at the company since 2022.
ARMEN GARO H
EXEC. CHAIR & PRINCIPAL OFF
BUY
2026-08-20 SEC
16,634
$9.8K
-19.1%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Aug 19, 2026.
  • The trade is 31.1% of the 53,533 shares held after it.
  • No other insider bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: EXEC. CHAIR & PRINCIPAL OFF ARMEN GARO H bought about $9.8K of PTIX on Aug 20, 2026, the largest insider purchase at the company since 2022.
ARMEN GARO H
EXEC. CHAIR & PRINCIPAL OFF
BUY
2026-08-20 SECtraded 2026-08-19
2,700
$945
-19.1%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Aug 11, 2026.
  • The trade is 7.3% of the 36,899 shares held after it.
  • No other insider bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: EXEC. CHAIR & PRINCIPAL OFF ARMEN GARO H bought about $945 of PTIX on Aug 19, 2026.
ARMEN GARO H
EXEC. CHAIR & PRINCIPAL OFF
BUY
2026-08-12 SECtraded 2026-08-11
2,220
$710
+80.0%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Aug 6, 2026.
  • The trade is 6.5% of the 34,199 shares held after it.
  • No other insider bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: EXEC. CHAIR & PRINCIPAL OFF ARMEN GARO H bought about $710 of PTIX on Aug 11, 2026.
ARMEN GARO H
EXEC. CHAIR & PRINCIPAL OFF
BUY
2026-08-10 SECtraded 2026-08-06
685
$151
+102.5%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Aug 5, 2026.
  • The trade is 2.1% of the 31,979 shares held after it.
  • No other insider bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: EXEC. CHAIR & PRINCIPAL OFF ARMEN GARO H bought about $151 of PTIX on Aug 6, 2026.
10 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 5 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$30.7K over 180 days
+$30.7K over 90 days
more than 71% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.8% of the float short (float per yahoo 2026-10-27) · 5.9 days to cover · settled 2026-10-15
below 76% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch PTIX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-78.3%12M
-96%-63%-30%+2%2025-102025-122026-022026-042026-062026-08 2026-08-21 · ARMEN GARO H bought $13.0K2026-08-20 · ARMEN GARO H bought $9.8K2026-07-30 · ARMEN GARO H bought $4.8K2026-08-05 · ARMEN GARO H bought $1.3K2026-08-19 · ARMEN GARO H bought $9452026-08-11 · ARMEN GARO H bought $7102026-08-06 · ARMEN GARO H bought $151
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns PTIX: institutional holders (13F)

13F holdings, latest reported quarter
DRW Securities, LLC
41,783 sh
$16.4K
FNY Investment Advisers, LLC
25,000 sh
$9

Congress trades in PTIX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

PTIX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $30.7K bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

PTIX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2025-04-01 to 2026-03-31
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
average equity is zero or negative
Return on assets
+117.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on capital employed
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
P/E, trailing
0.29x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2026-032025-032024-122023-12
Revenue$0$0$0$0
Operating income-$4.5M-$2.6M-$5.7M-$4.5M
Net income$1.4M-$3.6M-$5.5M-$5.0M
EPS (diluted)0.59-0.67-1.13-1.15
Operating cash flow-$2.8M-$1.8M-$4.2M-$3.7M
SEC XBRL, fiscal years, as known on 2026-10-28

PTIX Stock Sonar score 2/7 axes

Find similar shapesCompare
Insider conviction
63
Inputs
  • Net Form 4 buying (codes P and S), 180d$31K · 70 pct, sector of 429
  • Insider buyers, 180d1 · 56 pct, sector of 438
Risk and compliance
69
Inputs
  • Short interest, % of float+0.8% · 83 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+9.8% · 55 pct, sector of 511
5 not measured: Profitability, Financial health, Growth, Institutional and government, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; the filed year and its quarters do not reconcile, so the trailing figure is withheld
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

PTIX filings, in plain words

Are Protagenic Therapeutics, Inc.\new insiders buying or selling PTIX?

In the 180 days to 2026-10-28, Protagenic Therapeutics, Inc.\new insiders were net buyers, a net $30.7K across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-28, Protagenic Therapeutics, Inc.\new insiders were net buyers of PTIX, a net $30.7K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies